PARIS, France—To head off the risk of device-related thrombus after left atrial appendage (LAA) occlusion, a reduced dose of rivaroxaban may be a viable alternative to dual antiplatelet therapy (DAPT) ...

WASHINGTON -- Continuing use of rivaroxaban (Xarelto) at either 20 mg or 10 mg dose appears to reduce the risk of recurrent venous thromboembolism without increasing the risk for bleeding. "This is a ...

CHICAGO — In a post hoc analysis of the COMMANDER HF trial, treatment with low-dose rivaroxaban reduced risk for thromboembolic events in patients with worsening of chronic HF, reduced ejection ...

Pexidartinib is an oral small molecule that is believed to work by inhibiting colony stimulating factor-1 receptor (CSF1R). Both doses of Xarelto (10mg and 20mg) were superior to aspirin (100mg) in ...

The trial, presented at the American Heart Association (AHA) 2011 Scientific Sessions today, compared two doses of rivaroxaban with placebo in ACS patients. All patients were taking low-dose (75-100 ...

After ST-segment elevation myocardial infarction (STEMI), a twice-daily 2.5-mg dose of the novel anticoagulant rivaroxaban reduces thrombotic events, according to a subanalysis of the ATLAS ACS 2-TIMI ...

A lower dose formulation of Bayer and Janssen’s bloodthinner Xarelto has been approved by European regulators for preventing recurrent venous thromboembolism, expanding treatment options for patients.

Samuel Z. Goldhaber, MD: Hello. This is Dr. Sam Goldhaber for the Clot Blog on theheart.org talking to you from Brigham and Women's Hospital in Harvard Medical School. The topic today is the safety of ...

FDA Approves XARELTO® (rivaroxaban) to Treat Deep Vein Thrombosis and Pulmonary Embolism, and to Reduce the Risk of Recurrent Events RARITAN, NJ, November 2, 2012 – Janssen Pharmaceuticals, Inc.

Please provide your email address to receive an email when new articles are posted on . In the VOYAGER PAD trial, patients with symptomatic peripheral artery disease who underwent lower-extremity ...

In patients with stable atherosclerotic vascular disease, the combination of a low dose of rivaroxaban and aspirin is associated with a lower rate of cardiovascular outcomes but more major bleeding ...